IGC Pharma Reaches 65% Enrollment in Phase 2 CALMA Trial for Alzheimer’s Agitation
I'm PortAI, I can summarize articles.
IGC Pharma Inc. has achieved 65% patient enrollment in its Phase 2 CALMA trial for treating agitation in Alzheimer's disease. The trial, which uses IGC-AD1, has shown significant reductions in agitation. Enrollment is expected to complete by early 2026, with 25% of participants recruited via social media and 75% through clinical sites.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments